Flame

/ Dexcel

Tablets must be taken in the order directed on the package every day. One tablet is to be taken daily for 21 consecutive days. Each subsequent pack is started after a 7-day tablet-free interval during which time a withdrawal bleed occurs. This usually starts on day 2-3 after the last tablet and may not have finished before the next pack is started.
Please refer to the license holder for further details.

Oral Contraceptive

Presence or risk of arterial thromboembolism (ATE)
– Arterial thromboembolism – current arterial thromboembolism, history of arterial thromboembolism (e.g. myocardial infarction) or prodromal condition (e.g. angina pectoris)
– Cerebrovascular disease – current stroke, history of stroke or prodromal condition (e.g. transient ischaemic attack, TIA)
– Known hereditary or acquired predisposition for arterial thromboembolism, such as hyperhomocysteinaemia and antiphospholipid-antibodies (anticardiolipin-antibodies, lupus anticoagulant).
– History of migraine with focal neurological symptoms.
– A high risk of arterial thromboembolism due to multiple risk factors or to the presence of one serious risk factor such as:
• diabetes mellitus with vascular symptoms (micro or macroangiopathy)
• severe hypertension
• severe dyslipoproteinaemia
– Coronary disease
Presence or risk of venous thromboembolism (VTE)
– Venous thromboembolism – current VTE (on anticoagulants) or history of  VTE (eg. deep venous thrombosis [DVT] or pulmonary embolism [PE]).
– Known hereditary or acquired predisposition for venous thromboembolism, such as APC-resistance, (including Factor V Leiden), antithrombin-III-deficiency, protein C deficiency, protein S deficiency.
– Major surgery with prolonged immobilisation
– A high risk of venous thromboembolism due to the presence of multiple risk factors
* Thrombogenic valvulopathy;
* Thrombogenic arrhythmias;
* Suspected or confirmed breast cancer;
* Suspected or confirmed oestrogen-sensitive neoplasms (endometrial etc.);
* Hepatic adenoma or carcinoma;
* Severe hepatic disorders – until hepatic function has normalised;
* Abnormal vaginal bleeding of unknown cause;
* Suspected or confirmed pregnancy;
* Hypersensitivity to the active substances or to any of the excipients
* Pancreatitis associated with severe hypertriglyceridemia (current or history).
* This medicinal product is contraindicated for concomitant use with the medicinal products containing ombitasvir/paritaprevir/ritonavir and dasabuvir or medicinal products containing glecaprevir/pibrentasvir or sofosbuvir/velpatasvir/voxilaprevir.

Please refer to the license holder for further details.

Please refer to the license holder for further details.

Please refer to the license holder for further details.

Please refer to the license holder for further details.

Please refer to the license holder for further details.